GlaxoSmithKline plc announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for use in three eosinophil-driven diseases; hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA) and chronic rhinosinusitis with nasal polyps (CRSwNP). The CHMP opinion is one of the final steps in the marketing authorization procedure prior to approval decision by the European Commission. The three positive opinions are based on data from pivotal studies investigating the role of targeted IL-5 inhibition with mepolizumab in these eosinophil-driven diseases. Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell. HES and EGPA are both potentially life-threatening rare diseases. Inflammation in various tissues can cause a range of symptoms which are frequently severe. Standard of care for HES and EGPA often includes oral corticosteroids (OCS) and/or cytotoxic immune therapies. The availability of mepolizumab could provide patients with a new treatment option with the potential to improve clinical symptoms and reduce OCS use. Mepolizumab is already approved for use in Europe as an add-on treatment for patients with severe eosinophilic asthma. Epidemiological, clinical, and pathophysiological studies strongly suggest that CRSwNP and asthma are closely linked and often coexist. Additionally, patients with EGPA frequently have severe asthma. This overlap across eosinophil-driven diseases underscores the importance of understanding the complex role of eosinophils in disease. Mepolizumab has been studied in over 4,000 patients in a total of 41 clinical trials evaluating the role mepolizumab may play in targeting the underlying cause of inflammation and reducing eosinophils through IL-5 inhibition. Through ongoing research, GSK is committed to improving the lives of those living with disease associated with uncontrolled eosinophilic inflammation, continuously innovating in order to address the unmetneeds in this broad patient group.